Log in or Sign up for Free to view tailored content for your specialty!
Myeloproliferative Neoplasms News
ASH recognizes three Choosing Wisely Champions
SAN DIEGO — ASH today recognized the efforts of three clinicians who have implemented successful Choosing Wisely projects to improve the quality of care at their institutions.
Nivolumab, ipilimumab yield mixed results in myelodysplastic syndrome
SAN DIEGO — Patients with myelodysplastic syndrome responded favorably to ipilimumab and to nivolumab when they were administered in combination with azacitidine for first-line therapy, according to findings of a phase 2 trial presented at the ASH Annual Meeting and Exposition.
Log in or Sign up for Free to view tailored content for your specialty!
Oral vancomycin prevents C. difficile infection in allogeneic HSCT recipients
SAN DIEGO — Oral vancomycin, a standard antibiotic, effectively prevented Clostridium difficile infection in patients undergoing allogeneic hematopoietic stem cell transplantation, according to study results presented at the ASH Annual Meeting and Exposition.
ASH Annual Meeting to highlight major advances in malignant, benign hematology
SAN DIEGO — The HemOnc Today and Healio.com/HemOnc team will present comprehensive live coverage from the ASH Annual Meeting and Exposition beginning Dec. 3.
Momelotinib provides ‘some treatment benefit’ to patients with myelofibrosis
Gilead Sciences released topline data from two randomized phase 3 trials designed to evaluate its investigational JAK inhibitor momelotinib in patients with myelofibrosis, with one trial meeting its primary endpoint and the other failing to do so.
Decitabine especially effective in TP53–mutated AML, myelodysplastic syndrome
Patients with acute myeloid leukemia or myelodysplastic syndrome who harbored TP53 mutations or other cytogenetic abnormalities associated with unfavorable risk experienced favorable clinical responses with decitabine, according to a prospective, uncontrolled trial published in The New England Journal of Medicine.
ASH elects four to executive committee
ASH elected four new members to its executive committee.
Eight developments in bone marrow transplantation
Approximately 14,000 patients in the United States could benefit from a bone marrow transplant each year; however, only four out of every 10 will receive one, according to data from the DKMS organization.
MSKCC expert: Watson genomic sequencing service ‘expands expertise’ in precision medicine
The launch of the Watson for Genomics sequencing service has the potential to bring precision medicine to cancer treatment centers worldwide, according to a press release issued by IBM Watson Health and Quest Diagnostics.
ASCO guideline recommends early integration of palliative, standard oncology care
Patients with advanced cancer should receive dedicated, early palliative care concurrently with standard oncology treatment, according to ASCO’s updated guidelines published in Journal of Clinical Oncology.